Cargando…

Quality by Design risk assessments supporting approved antibody products

Detalles Bibliográficos
Autor principal:	Kelley, Brian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2016
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5098449/ https://www.ncbi.nlm.nih.gov/pubmed/27618387 http://dx.doi.org/10.1080/19420862.2016.1232218

Ejemplares similares

Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015–2020
por: Arondekar, Bhakti, et al.
Publicado: (2022)

The current landscape of the FDA approved companion diagnostics
por: Jørgensen, Jan Trøst
Publicado: (2021)

The hospital exemption pathway for the approval of advanced therapy medicinal products: an underused opportunity? The case of the CAR-T ARI-0001
por: Trias, Esteve, et al.
Publicado: (2022)

First vaccine approval under the FDA Animal Rule
por: Beasley, David W C, et al.
Publicado: (2016)

Challenges and opportunities for improving access to approved neonatal drugs and devices
por: Lewis, Tamorah, et al.
Publicado: (2022)

The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA.
por: Olivier, Timothée, et al.
Publicado: (2022)

Fast Methods for Drug Approval: Research Perspectives for Pandemic Preparedness
por: Abdin, Ahmad Yaman, et al.
Publicado: (2023)

An open science pathway for drug marketing authorization—Registered drug approval
por: Naudet, Florian, et al.
Publicado: (2021)

Japan's COVID‐19 treatment strategy: An examination of approved oral medications
por: Higuchi, Yuka, et al.
Publicado: (2023)

Supporting the production of pharmaceuticals in Africa
por: Dong, Jicui, et al.
Publicado: (2016)

The FDA-Approved Essure Device Counseling Order Fails to Promote Patient Empowerment
por: Gunn, Christine M., et al.
Publicado: (2019)

A Patient‐Centric Model for Discontinuation of a Single‐Sourced Approved Drug
por: Caplan, Arthur, et al.
Publicado: (2019)

Conditional early approval for new drug applications in Japan: Current and emerging issues
por: Tanaka, Mototsugu, et al.
Publicado: (2023)

An insider's perspective on FDA approval of aducanumab
por: Wang, Yaning
Publicado: (2023)

Modeling and Simulation to Optimize the Design and Analysis of Confirmatory Trials, Characterize Risk–Benefit, and Support Label Claims
por: Marshall, S F, et al.
Publicado: (2013)

Overview of the Side-Effects of FDA- and/or EMA-Approved Targeted Therapies for the Treatment of Hematological Malignancies
por: Constantinescu, Catalin, et al.
Publicado: (2020)

FDA expedited approval and implications for rational formulary and health plan design
por: Ferries, Erin A, et al.
Publicado: (2021)

Designing m-Health interventions for precision mental health support
por: Bidargaddi, N., et al.
Publicado: (2020)

Premarket Approval Through the 510(k) Process: Lessons from the Translation Process of Magnetic Resonance Elastography
por: Aponte Ortiz, Jaime A., et al.
Publicado: (2018)

Regulators' Advice Can Make a Difference: European Medicines Agency Approval of Zynteglo for Beta Thalassemia
por: Schuessler‐Lenz, Martina, et al.
Publicado: (2019)

Fragility of randomized trials supporting cancer drug approvals stratified by approval pathway and review designations
por: Wilson, Brooke E., et al.
Publicado: (2021)

Recommendations for the design of laboratory studies on non-target arthropods for risk assessment of genetically engineered plants
por: Romeis, Jörg, et al.
Publicado: (2010)

Monoclonal Antibodies Approved for Cancer Therapy
por: Baldo, Brian A.
Publicado: (2016)

On what basis did Health Canada approve OxyContin in 1996? A retrospective analysis of regulatory data
por: Pappin, Jessie, et al.
Publicado: (2022)

Directly Observed Care: Crossing the Chasm of Quality Measurement
por: Kelley, A. Taylor, et al.
Publicado: (2022)

Connecting the sequence dots: shedding light on the genesis of antibodies reported to be designed in silico
por: Vásquez, Maximiliano, et al.
Publicado: (2019)

Pharmacogenetic Labeling of FDA-Approved Drugs: A Regulatory Retrospective
por: Drozda, Katarzyna, et al.
Publicado: (2018)

Mendelian Randomization Studies Promise to Shorten the Journey to FDA Approval
por: Roberts, Robert
Publicado: (2018)

Air Pollution and Atherosclerosis: New Evidence to Support Air Quality Policies
por: Künzli, Nino
Publicado: (2013)

Virtualising the School During COVID-19 and Beyond in Africa: Infrastructure, Pedagogy, Resources, Assessment, Quality Assurance, Student Support System, Technology, Culture and Best Practices
por: Owolabi, Joshua Oladele
Publicado: (2020)

An in-silico evaluation of COVID-19 main protease with clinically approved drugs
por: Tachoua, Wafa, et al.
Publicado: (2020)

Approved gene therapies in Australia: coming to a store near you
por: Mallik, Shreyashee, et al.
Publicado: (2022)

Quality and Safety Requirements for Sustainable Phage Therapy Products
por: Pirnay, Jean-Paul, et al.
Publicado: (2015)

The Future of Health Is Self-Production and Co-Creation Based on Apomediative Decision Support
por: Dowie, Jack, et al.
Publicado: (2018)

Chemistry, structure and function of approved oligonucleotide therapeutics
por: Egli, Martin, et al.
Publicado: (2023)

Study design considerations to assess the impact of potential drug–drug interactions in first‐in‐human studies in oncology drug development
por: Subramaniam, Sriram, et al.
Publicado: (2023)

A Practical Guide to Design and Assess a Phylogenomic Study
por: Lozano-Fernandez, Jesus
Publicado: (2022)

Quality changes to approved biotherapeutic product: Simulated case studies on reporting categories & supporting data requirements
por: Hamel, Hugo, et al.
Publicado: (2019)

Risk Assessment and Alternatives Assessment: Comparing Two Methodologies
por: Whittaker, Margaret H.
Publicado: (2015)

Bisphenol A and Risk Assessment
por: Politch, Joseph A.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_qr4efv2lt93trjc20ur1btd02a